LYRA - Why Lyra Therapeutics Stock Is Down 93% Today | Benzinga
Lyra Therapeutics Inc (NASDAQ:LYRA) shares are trading lower by 93% to $0.30 during Monday’s session after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
What Happened?
Lyra Therapeutics released disappointing results from its Phase 3 ENLIGHTEN 1 trial, evaluating LYR-210 for chronic rhinosinusitis (CRS). LYR-210 did not meet the primary endpoint of significantly improving CRS symptoms compared to the sham control at 24 weeks.
Despite improvements in some secondary measures, such as the Sino-Nasal Outcome Test (SNOT-22) score, ethmoid sinus opacification did not significantly improve. The trial, which enrolled 190 patients, is ongoing, ...